

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 4 of Short Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.11300 - CINVEN / SYNLAB

SECTION 4

Description of the concentration

On 25 October 2023, the European Commission received notification of a proposed concentration pursuant to Article 4 of the EUMR by which the Fifth Cinven Fund, managed by Cinven Capital Management (V) General Partner Limited, intends to acquire indirect sole control, within the meaning of Article 3(1)(b) of the EUMR, of SYNLAB AG, (together with its subsidiaries, “**SYNLAB**”) (the “**Transaction**”), pursuant to a public acquisition offer announced on 29 September 2023.

The concentration will be accomplished by way of purchase of shares.

Cinven is a private equity business engaged in the provision of investment management and investment advisory services to a number of investment funds. The companies in Cinven’s portfolio of investments are active in a variety of sectors across a range of jurisdictions. Cinven Capital Management (V) General Partner Limited is incorporated in Guernsey.

SYNLAB provides medical diagnostic services and special diagnostics, primarily in the sector of human medicine, across a range of jurisdictions. The services include: (i) clinical laboratory testing; (ii) anatomic pathology diagnostics; and (iii) diagnostic imaging; (iv) human genetics; and (v) value adding services. SYNLAB AG is listed on the Frankfurt Stock Exchange and incorporated in Germany. SYNLAB AG is not controlled by any single entity.